Skip to main content
Clinical Trials/NCT03217474
NCT03217474
Unknown
Not Applicable

A Randomized Controlled Clinical Trial of Corneal Debridement for the Treatment of Herpes Simplex Epithelial Keratitis

Chunxiao Wang1 site in 1 country100 target enrollmentJuly 20, 2017

Overview

Phase
Not Applicable
Intervention
FLDEB
Conditions
Herpes Simplex Keratitis
Sponsor
Chunxiao Wang
Enrollment
100
Locations
1
Primary Endpoint
Healing time
Last Updated
8 years ago

Overview

Brief Summary

The purpose of the study is to learn if adding femtosecond laser-assisted corneal debridement to a standard therapy of oral ganciclovir can help shorten the healing time of herpes simplex epithelial keratitis (HSK).

Registry
clinicaltrials.gov
Start Date
July 20, 2017
End Date
December 30, 2019
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Chunxiao Wang
Responsible Party
Sponsor Investigator
Principal Investigator

Chunxiao Wang

Clinical investigator

Sun Yat-sen University

Eligibility Criteria

Inclusion Criteria

  • Aged between 18 and 80 years old;
  • Epithelial ulceration in a dendritic or geographic pattern, characteristic of infection with herpes simplex virus, and within 7 days of onset;
  • Ulcer's stromal involvement \< 120 micron, as indicated by anterior segment optical coherence tomography;
  • Informed consent signed by patient or legal guardian. Having the ability to comply with study assessments for the full duration of the study.

Exclusion Criteria

  • Clinical signs of a cause other than herpes simplex virus for the epithelial keratitis;
  • Antivirus or corticosteroid treatment within 6 months;
  • Active stromal keratitis or iritis;
  • History of allergy or adverse reaction to ganciclovir;
  • High myopia with a spherical equivalent of -15.0 D or less;
  • Corneal or ocular surface infection within 30 days prior to study entry;
  • Ocular surface malignancy;
  • Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;
  • Renal failure with creatinine clearance\< 25ml/min;
  • Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L;

Arms & Interventions

FLDEB combined with GCV orally

Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.

Intervention: FLDEB

FLDEB combined with GCV orally

Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.

Intervention: Ganciclovir (GCV)

FLDEB combined with GCV orally

Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.

Intervention: Femtosecond laser

GCV orally

Ganciclovir (GCV) orally only

Intervention: Ganciclovir (GCV)

Outcomes

Primary Outcomes

Healing time

Time Frame: 14 ± 1 days

Time to complete corneal epithelial healing

Secondary Outcomes

  • Corneal opacity and vascularization(Baseline, 14 ± 1 days, 3 months)
  • Best-corrected visual acuity(Baseline, 14 ± 1 days, 3 months)
  • Corneal sensation(Baseline, 14 ± 1 days, 3 months)
  • Corneal re-epithelization(14 ± 1 days)
  • Corneal power and astigmatism(Baseline, 14 ± 1 days, 3 months)
  • Recurrence(3 months)

Study Sites (1)

Loading locations...

Similar Trials